Report of Foreign Issuer (6-k)
06 February 2019 - 1:01AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2019
BioLineRx Ltd.
(Translation of registrant’s name into English)
2 HaMa’ayan Street
Modi’in 7177871, Israel
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:
Yes ☐ No ☒
On February 5, 2019, the registrant issued the press release which is filed as
Exhibit 1
to this Report on Form 6-K.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
BioLineRx Ltd.
|
|
|
|
|
|
|
By:
|
/s/
Philip Serlin
|
|
|
|
Philip Serlin
|
|
|
|
Chief Executive Officer
|
|
|
|
|
|
BioLineRx (NASDAQ:BLRX)
Historical Stock Chart
From Apr 2024 to May 2024
BioLineRx (NASDAQ:BLRX)
Historical Stock Chart
From May 2023 to May 2024